10-walentna szczepionka przeciwpneumokokowa skoniugowana z białkiem D z nietypowalnej pałeczki hemofilnej (PHiD-CV). Nowa koncepcja - perspektywa na przyszłość?

In wide population vaccinations PhiD-CV appeared to be sufficiently immunogenic in 2+1 schedule. In Canadian studies on effectiveness of PHiD-CV appeared to be more effective in reducing IPD in comparison to previously applicated PCV7. At the moment there are in the course two important randomized controlled studies. In COMPAS efficacy study in the South America >20% reduction of consolidated CAP has been observed. In Finland the efficacy study (FinIP) on incidence of AOM and IPD is in the course. On the basis of the last epidemiology study of IPD in Poland it is possible to calculate that PHiD-CV cover more than 70% serotypes present in Poland and a new PCV13-86%.